SDZ.SW Sandoz Group AG (SIX) market closed 18 Feb 2026: CHF66.68 shows momentum signal

The SDZ.SW stock closed the Swiss session at CHF66.68 on 18 Feb 2026 after trading 832,327 shares, keeping it among the market’s most active names. The one-day change was -0.71%, while year-to-date performance sits at 16.53%. Investors are watching an upcoming earnings release on 25 Feb 2026 and mixed valuation metrics such as EPS CHF0.40 and PE 166.70. This article breaks down price drivers, Meyka AI grade and forecast, technical signals, and near-term risks for Sandoz Group AG on SIX.

SDZ.SW stock market snapshot and intraday drivers

Sandoz Group AG (SDZ.SW) traded in a CHF66.06–CHF67.28 intraday range and closed at CHF66.68 on SIX. Volume hit 832,327, above the 50-day average of 736,047, giving a relative volume of 1.13. One-day price movement was -0.48 or -0.71%, with the 52-week range from CHF26.25 to CHF67.34. Traders flagged momentum after recent multi-month gains and continued interest from active Swiss healthcare rotation.

SDZ.SW stock fundamentals and upcoming earnings

Sandoz reports EPS of CHF0.40 and a trailing PE of 166.70, reflecting strong price gains versus modest reported earnings. Revenue per share is CHF21.58 and book value per share is CHF20.42, producing a price-to-book near 4.27. The company announces results on 25 Feb 2026, a date likely to drive short-term volatility and volume.

Balance sheet and cash flow metrics show operating cash flow per share CHF2.20 and free cash flow per share CHF0.73. Net debt to EBITDA and interest coverage suggest manageable leverage, but long inventory cycles raise working capital sensitivity.

Meyka AI grade and SDZ.SW stock forecast

Meyka AI rates SDZ.SW with a score of 68.55 out of 100 and assigns a Grade B (HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Meyka AI’s forecast model projects a one-year price of CHF81.59, implying an upside of 22.38% from the current CHF66.68. Forecasts are model-based projections and not guarantees. Investors should treat the projection as scenario-based guidance ahead of the earnings release.

SDZ.SW stock technicals and trading signals

Technical indicators point to positive momentum for SDZ.SW stock. The RSI is 68.80, MACD histogram is positive at 0.43, and ADX reads 31.26, indicating a strong trend. Bollinger Bands sit Upper CHF67.31 / Middle CHF63.11 / Lower CHF58.90, showing limited immediate upside to the band top.

Short-term moving averages are above the 50-day and 200-day averages (Price Avg 50 CHF60.37, Price Avg 200 CHF50.81), supporting the bullish bias. Volume and on-balance volume trends confirm institutional interest, but overbought oscillators warn traders to expect pullbacks near resistance.

SDZ.SW stock valuation, price targets and scenarios

Valuation metrics for SDZ.SW stock show P/S 4.03, P/B 4.27, and EV/EBITDA 57.45, reflecting a premium to many peers in the healthcare sector. Given the premium multiple, we outline scenario targets: conservative CHF60.00, base CHF81.50 (Meyka model), and bullish CHF110.00. These targets reflect earnings sensitivity and biosimilars growth assumptions.

Investors should compare Sandoz’s multiples to large Swiss peers and to generic manufacturers. Peer moves, regulatory updates, and margin trends will determine whether the premium multiple holds.

SDZ.SW stock risks and sector outlook

Key risks for SDZ.SW stock include pricing pressure in generics, inventory cycles, and regulatory setbacks in biosimilars. Financial growth metrics show revenue contraction last year and net income volatility. Debt-to-equity of 0.65 and interest coverage of 4.71 indicate leverage that requires monitoring.

On the opportunity side, Sandoz benefits from scale in generics and biosimilars and rising demand for cost-effective medicines. Sector peers such as Roche and Novartis influence sentiment; read broader healthcare moves at Investing.com Roche coverage and watch Swiss consumer sector context at Investing.com Lindt coverage. Also see Sandoz on Meyka for live data: Sandoz SDZ.SW on Meyka.

Final Thoughts

SDZ.SW stock closed at CHF66.68 on 18 Feb 2026 after a busy session and above-average volume. Fundamentals show solid revenue per share and book value, but the trailing PE of 166.70 and high EV/EBITDA reflect a stretched valuation. Meyka AI rates SDZ.SW 68.55/100 (Grade B, HOLD) and projects CHF81.59 in one year, an implied 22.38% upside from today. Technical indicators show momentum with RSI near 68.80 and ADX 31.26, supporting continued active trading before earnings on 25 Feb 2026. Short-term traders should watch volume and oscillators for pullback signals. Long-term investors must weigh biosimilars growth against valuation risk and working capital cycles. Use the Meyka forecast as one scenario, not a guarantee, and combine it with company results and peer moves ahead of the earnings release.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.